Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spil Cord Injury - Overview
Spil Cord Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spil Cord Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spil Cord Injury - Companies Involved in Therapeutics Development
Spil Cord Injury - Drug Profiles
Spil Cord Injury - Dormant Projects
Spil Cord Injury - Discontinued Products
Spil Cord Injury - Product Development Milestones
Featured News & Press Releases
Sep 17, 2022: NervGen Pharma presenting at upcoming Military Health System Research Symposium and the 61st Intertiol Spil Cord Society Annual Scientific Meeting
May 20, 2022: Birmingham research brings hope for spil cord injury treatment
May 18, 2022: NervGen hosting ppanel discussion with leading experts at the 2022 Annual Meeting of American Spil Cord Injury Association (ASIA)
May 12, 2022: NervGen Pharma receives approval to proceed to the fil dose cohort in phase 1 clinical trial of NVG-291
Mar 31, 2022: NervGen presenting interim phase 1 clinical trial data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Mar 23, 2022: NervGen Pharma to present at 2022 virtual growth conference presented by Maxim Group
Mar 15, 2022: NervGen Pharma receives approval from Safety Review Committee to proceed to second cohort in multiple ascending dose portion of phase 1 clinical trial of NVG-291
Jan 10, 2022: NervGen Pharma announces intent to conduct groundbreaking spil cord injury clinical trial in exclusive partnership with Shirley Ryan AbilityLab, 1-Ranked Hospital in Physical Medicine & Rehabilitation
Dec 22, 2021: NervGen Pharma receives ethics board approval for multiple ascending dose portion of NVG-291 phase 1 trial
Nov 04, 2021: NervGen presents additiol phase 1 clinical trial data for NVG-291 at Neuroscience 2021 / safety review committee provides recommendation to proceed to multiple ascending dose portion of the trial
Oct 27, 2021: NervGen Pharma announces spil cord injury clinical advisory board
Oct 18, 2021: NervGen presents interim phase 1 clinical trial data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 demonstrated to be well tolerated along with a favorable pharmacokinetic profile
Sep 27, 2021: NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials
Sep 12, 2021: NervGen Pharma presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 08, 2021: Phase 2 Trial of MT-3921 initiated for treatment of spil cord injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Spinal Cord Injury - Dormant Projects, 2022
Spinal Cord Injury - Dormant Projects, 2022 (Contd..1)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..2)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..3)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..4)
Spinal Cord Injury - Discontinued Products, 2022